TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06077357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAMPA Test
Description: The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAMPA Test
Description: The TAMPA test, abbreviated from Tampa Scale for Kinesiophobia, is a scale used to assess fears related to pain. This scale is employed to evaluate the fear of pain and avoidance behaviors associated with it. By measuring individuals' attitudes and fears towards pain, the TAMPA test helps identify their emotional and behavioral responses in this area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (JAMAR) Muscle Test
Description: The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.
Study: NCT04917432

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intravascular ultrasound (IVUS)
Description: Intravascular imaging using a specialized catheter delivered through intra-arterial approach to reach the coronaries to guide CTO-PCI procedure and optimize the results after wire crossing.
Study: NCT05395689

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year
Study: NCT04917432

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional CTO PCI (non-IVUS guided)
Description: Non-IVUS guided CTO PCI for wiring but may be used for results optimization after wire crossing
Study: NCT05962437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-guided digital Acceptance and Commitment Therapy
Description: Smartphone-based mobile health application (app) that delivers a self-guided, evidence-based ACT program tailored to the management of FM. This investigational digital therapeutic, referred to herein as STANZA, was inspired by a web-based ACT program for FM validated by University of Manitoba and was recently granted De Novo clearance by the U.S. FDA. The app delivers ACT in 15- to 20-minute daily doses over the course of 12 weeks without the involvement of healthcare providers. The program consists of interactive educational materials that teach ACT skills which are reinforced experientially via values exploration and identification, mindfulness, and relaxation exercises. Values-based assignments follow each lesson to assist patients in incorporating ACT skills into their daily lives. Uniquely, STANZA teaches additional skills, including self-guided physical exercise and pacing daily activities via a personally customized stepwise, gradual approach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FM symptom tracking app (FM-ST)
Description: Based on the same platform as STANZA, FM-ST enables self-guided daily tracking of patient-reported symptoms and functioning. Symptom tracking is commonly used in chronic pain management. FM-ST also provides access to educational materials relevant to FM and general health but does not provide any psychotherapy or healthcare professional involvement. This app mitigates potential expectation, treatment time and attention, and healthcare provider interaction biases that often occur in chronic pain studies that utilize passive comparison conditions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Usual care is mainly carried out by general practitioners and specialists in regular consultations, commonly consisting of face-to-face visits to monitor the physical and emotional status of the patient. Clinicians usually provide advice about physical exercise, diet, etc., and prescribe pharmacotherapy (pain medications, hypnotics and antidepressants)
Study: NCT05474508

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing
Description: Exercise programs will consist of 1 set of contractions per day and each set will include 30 repetitions for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: Exercise protocol consist of at least 150 minutes of moderate-intensity aerobic activity every week dividing the 150 minutes into 30-minute workouts on 5 days of the week or into smaller 10-minute sessions throughout each day will be carried out for 6 weeks.
Study: NCT06073171

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sample
Description: 7.5 mL will be sampled on EDTA tube for each patient

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cutaneous biopsy
Description: 4 mm of damaged skin will be sampled after a premedication with lidocaine gel for 4 patients

Intervention type: GENETIC
Group type: OTHER
Intervention: High troughput sequencing of human's exome
Description: Sequencing on Illumina NovaSeq6000 platform, using the Twist Bioscience Human Core Exome kit + IntegraGen content, average 37Mb. This sequencing will be realised by external provider, IntegraGen society.
Study: NCT05059652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning
Description: The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Ischemic Preconditioning
Description: The Ischemic Preconditioning (IPC) is characterized by the application of brief periods of circulatory occlusion (ischemia) and reperfusion of a limb in the minutes to hours that precede the exercise through the insufflations and deflations of a pressure cuff.
Study: NCT04921345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive subcutaneous (SC) injection of 10, 20 or 30 milligrams (mg) nemolizumab, every 4 weeks (Q4W) for 52 weeks with a loading dose of 20, 40 or 60 mg at Day 1 based on the body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
Study: NCT06077357

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (JAMAR) Muscle Test
Description: The JAMAR Muscle Test is a widely used clinical assessment tool for evaluating hand grip strength. It involves using a device called a dynamometer to measure the force exerted by a person's hand when squeezing the instrument. This test provides valuable information about an individual's upper body strength, which can be important in various medical and rehabilitative contexts. The JAMAR Muscle Test is often utilized in physical therapy, sports medicine, and other healthcare fields.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Severity Scale
Description: The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fatigue Severity Scale
Description: The Fatigue Severity Scale (FSS) is a self-report questionnaire used to assess the severity of fatigue in individuals. It consists of nine items that measure the impact of fatigue on various aspects of daily life, such as physical functioning, motivation, and mental clarity. The FSS is commonly used in clinical settings and research studies to quantify the level of fatigue experienced by individuals with various medical conditions, including chronic illnesses, neurological disorders, and mental health conditions. It provides valuable information for healthcare professionals in understanding and managing fatigue-related symptoms.
Study: NCT05442879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knowledge Translation Intervention
Description: The KT intervention utilizes the communications between the teams and the researchers to promote implementation of the ACL-IPPs. The meetings will provide opportunities for mutually beneficial learning from the researchers, and feedback from the coaches on how to best implement strategies through local barriers in order to facilitate necessary changes to promote ACL-IPP usage while adhering to clinical practice guideline recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational handout
Description: Educational handout describing a commonly cited ACL-IPP.
Study: NCT05744063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emapalumab-Lzsg 5 MG/ML [Gamifant]
Description: iv
Study: NCT05663619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction during dental treatment of children.
Description: One of the behavior management techniques used with children in dental clinics to allow for delivering quality dental treatment is the use of Virtual Reality distraction (VRD). Virtual reality distraction immerses the patient in an environment generated by a computer and works by simulating as many senses as possible: vision, hearing, and touch. In dentistry, VRD has exhibited great results in reducing anxiety and fear among children and adolescents compared to those who received no intervention or more conventional BMTs. VRD may allow the dentist to provide more efficient dental treatments, ranging from simple anesthesia to more advanced forms of dental treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: watching cartoon on screen as distraction during dental treatment of children.
Description: The American Academy of Pediatric Dentistry (AAPD) recommends a series of non-pharmacological behavior management techniques for managing children during dental care including distraction. Distraction is defined by AAPD as the technique of diverting the patient's attention from what may be perceived as an unpleasant procedure. It is widely used as it provides an effective and relaxing experience during treatment.
Study: NCT04830722

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sculptra Aesthetic
Description: One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra Aesthetic
Description: One treatment side treated with Sculptra will be compared to the other side treated with bacteriostatic water (placebo) -same volume
Study: NCT04756401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO
Study: NCT05515770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injection
Description: Long action cabotegravir injection
Study: NCT06530030

Intervention type: DRUG
Intervention: efanesoctocog alfa
Description: All treatment decisions must be made independent of study participation and study-related visits/assessments are not intended to inform treatment decisions. No study medication is provided as part of study participation.
Study: NCT05755035

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive SC infusion of TAK-881.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive SC infusion of TAK-881.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive SC infusion of TAK-881.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants will receive SC infusion of HYQVIA.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants will receive SC infusion of HYQVIA.
Study: NCT05868226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX148
Description: CD47 Inhibitor: A fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPα) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human immunoglobulin (Ig) G1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fam-Trastuzumab Deruxtecan-Nxki
Description: Antibody-drug conjugate (ADC): A recombinant humanized anti-human HER2 IgG1 monoclonal antibody, conjugated with linker to a Topoisomerase I inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Bispecific HER2 antibody: A humanized, bispecific, immunoglobulin G isotype 1 (IgG1)-like antibody directed against the juxtamembrane extracellular domain (ECD4) and the dimerization domain (ECD2) of human epidermal growth factor receptor 2 (HER2).
Study: NCT04921345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants will receive SC injection of 5, 10 or 15 mg nemolizumab, Q4W for 52 weeks with a loading dose of 10, 20 or 30 mg at Day 1 based on the body weight.
Study: NCT05868226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Small molecule tyrosine kinase inhibitor (TKI) of HER2 (oral drug).
Study: NCT05524428

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Implementation Science Strategy
Description: The investigators will be conducting focus groups and identifying barriers and facilitators, and the investigators will be matching identified barriers and facilitators to implementation strategies at the patient, provider, and system level which the investigators will be testing using rapid-cycle methods.
Study: NCT05457634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combustible Cigarette
Description: Subjects smoke their Usual Brand Combustible Cigarette, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu Disposable A
Description: Subjects use the blu disposable e-cigarette with flavor A, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu Disposable B
Description: Subjects use the blu disposable e-cigarette with flavor B, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu Disposable C
Description: Subjects use the blu disposable e-cigarette with flavor C, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu Disposable D
Description: Subjects use the blu disposable e-cigarette with flavor D, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blu Disposable E
Description: Subjects use the blu disposable e-cigarette with flavor E, 2.4% nicotine, for 2 consecutive product use sessions. 1. Defined session: 10 puffs, each 30 seconds apart. 2. Ad libitum session: 60 minutes ad-libitum use.
Study: NCT04651595

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caudal block
Description: caudal block with low dose bupivicaine 0.25% to preserve tone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: morphine to control pain and avoid using muscle relaxant
Study: NCT05269992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real food products
Description: As per arm/group descriptions.
Study: NCT05388812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual Vocational Rehabilitation (TAU-VR)
Description: TAU-VR Services may include 1) Compensated Work Therapy-Transitional Work (CWT-TW) assignment in a set-aside, minimum-wage, short-term job, typically in the VA setting (approximately 50% of the Veterans randomized to TW in past studies conducted by the investigators actually engaged in TW assignment) or 2) CWT-Community-Based Employment Services (CWT-CBES) which involves a community job search, placement in a competitive job, with limited follow-along support that typically ends after the Veteran is working in his/her first job

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Description: The IPS model involves the following important domains: competitive employment, eligibility based on client choice of employment, integration of IPS and treatment team personalized counseling, rapid job search, systematic job development, and time-unlimited and individualized support.
Study: NCT06347926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires given before and after photobiomodulation
Description: Questionnaires given at 1 month, 6 months and 12 months
Study: NCT05559463

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ITIS diet
Description: anti-inflammatory (ITIS) diet for 28 days
Study: NCT05348837

Intervention type: PROCEDURE
Intervention: Deep brain stimulation
Description: Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.

Intervention type: PROCEDURE
Intervention: Deep brain stimulation
Description: Candidacy for DBS implantation will be determined by the treating team, which includes a neurologist, neurosurgeon, neuropsychologist, neuro-radiologist, and palliative care physician.
Study: NCT06097845

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Ultrasound
Description: Patients who underwent reconstructive sonolucent cranioplasty will receive standard of care postoperative imaging (i.e. CT, MRI) in addition to ultrasound imaging. Ultrasound imaging will be performed by clinicians using FDA-approved ultrasound devices (GE Venue Go, Fujifilm Sonosite X-Porte, GE Volusion E10 and Clarius HD3 etc.) currently used in routine clinical practice.
Study: NCT05429697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMT-NK inj.+Pembrolizumab
Description: SMT-NK inj. will be administered as an intravenous (IV) infusion on Day 1,Day 7 of each 21-day cycle.~Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
Study: NCT06638775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fesia Grasp
Description: The Fesia Grasp device is based on the superficial electrical stimulation of the forearm musculature to provoke flexion and extension movements of the wrist, thumb, index finger and fingers 3, 4 and 5.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLOBUS ELITE
Description: is an electro-stimulator designed for sport and fitness, but with special attention also for beauty treatments thanks to the new sequential stimulation currents, excellent for their draining effects.
Study: NCT06638346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened FIFA 11+ warm-up exercise program
Description: The shortened FIFA11+ incorporates 5 exercises from the original FIFA11+ part 2 and 3: Sideways bench, single-leg stance, squats, jumping and plant and cut (refer to FIFA 11+ manual). All exercises, except plant and cut, have three levels of difficulty. Difficulty progression will follow FIFA11+ guideline option C where all players progress to the next level of all exercises after 3 or 4 weeks. This program is done on artificial turf.~Coaches will be trained on FIFA guidelines by the primary investigator and provided with explanatory placards and the FIFA 11+ manual. The primary investigator will conduct checks twice a week with the coaches to address any questions and review the program. Only the shortened FIFA11+ group will receive verbal feedback as per FIFA11+ guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian warm-up exercise program
Description: The control group engages in a Brazilian warm-up. The warm-up consists of exercises performed in standing and while running including the following:~* Performed in standing: Circular Arms (20-30 sec total), Opening and closing of the hips (20-30 sec total).~* Performed while running back and forth on the field: Jogging (2 times), high kicks (2 times), glute kicks (2 times)~* Performed while running forward (exercise), then small jog back without performing the exercise: hand-to-heel touches (2 times), knee and heel touches (2 times each side), side leg swings (2 times) and progressive sprint 80-90% speed (2 times).~Coaches will supervise the session but will not be allowed to give verbal feedback. This program is done on artificial turf.